First-in-Class Covalent Inhibitors of PFKFB3: Discovery and Characterization in PDAC Models

Added on:
22 Jul, 2026

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer, driven by metabolic reprogramming. Since direct glycolytic enzyme inhibition is limited by toxicity, indirect glycolysis modulation through inhibition of the kinase activity of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) may offer a safer therapeutic strategy. Herein, we report the first-in-class covalent PFKFB3 inhibitor (6), targeting a previously unexplored cysteine. Enzyme assays, site-directed mutagenesis, and mass spectrometry confirmed covalent binding and kinetic selectivity for PFKFB3. Compound 6 reduced viability across multiple PDAC cell lines and suppressed PDAC growth in zebrafish xenografts. Its combination with standard chemotherapeutics revealed synergistic effects. Although the limited cellular activity of 6 restricts its use as a chemical probe in biological studies, we proved for the first time the druggability of a previously unexplored cysteine in PFKFB3. Our work represents a significant achievement in the selective targeting of this kinase, paving the way for an innovative mechanism of action for PFKFB3 inhibitors.

  • Fiore A1
  • Scarano A2
  • Antonini G3
  • Corfù AI3
  • Sicuro L4,5
  • Faggiano S2,6
  • Celesia A1,3
  • Tesoriero C7
  • Pacchiana R1
  • Vettori A7
  • Arslanbaeva L8
  • Minucci S8,9
  • Pallavicini I8
  • Mollica L4
  • Tamborini L3
  • Donadelli M1
  • Conti P3
  • Bruno S2
  • Borsari C3
  •   1Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry, University of Verona, 37134 Verona, Italy
  • 2Department of Food and Drug, University of Parma, Parco Area delle Scienze 23/a, 43124 Parma, Italy
  • 3Department of Pharmaceutical Sciences, University of Milan, Via Mangiagalli 25, 20133 Milan, Italy
  • 4Department of Medical Biotechnologies and Translational Medicine c/o L.I.T.A/University of Milan, Via F.lli Cervi 93, 20090 Segrate (MI), Italy
  • 5Fondazione IRCCS Ca’Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, 20133 Milan, Italy
  • 6Institute of Biophysics, National Research Council (CNR), Via G. Moruzzi 1, 56124 Pisa, Italy
  • 7Department of Biotechnology, University of Verona, 37134 Verona, Italy
  • 8Department of Experimental Oncology, IEO European Institute of Oncology IRCSS, 20139 Milan, Italy
  • 9Department of Oncology and Hematology-Oncology, University of Milan, 20122 Milan, Italy
First-in-Class Covalent Inhibitors of PFKFB3
Read the publication that featured this abstract